11 February, 2026 | Jabbar Ali - MPharm
Wegovy is licensed in the UK for weight management, but it's not just about the number on the scale. Because semaglutide - the active ingredient in Wegovy - works on appetite, blood sugar and inflammation throughout the body, researchers have spent the last few years investigating whether it offers meaningful benefits beyond weight loss too - and in several areas, large clinical trials have found genuine answers.
This guide walks through what the evidence actually shows for heart, liver, kidney and PCOS-related effects, where Wegovy may help with sleep apnoea, and what very early research suggests about cravings and addictive behaviour. A quick note before you dive in: not all of these findings carry the same weight. Some come from large, well-designed clinical trials — solid evidence doctors trust. Others are early results that look promising but aren't proven yet. We've flagged which is which along the way, so you walk away with a realistic picture — not a rosier one than the science actually supports.
Carrying excess weight increases the risk of heart problems and related cardiovascular conditions. Wegovy can help lower such risks.
This is based on the SELECT trial[1], a large study of people with a BMI of 27kg/m2 or above who had existing heart disease but no diabetes. Participants took either Wegovy 2.4mg once a week or a placebo, and were followed for a mean of 3.3 years for the cardiovascular endpoint. The results showed:
On the strength of these findings, Wegovy's UK licence has been extended beyond weight management alone: it is now also licensed by the MHRA to reduce the risk of major cardiovascular events, including heart attack and stroke, in adults with established cardiovascular disease and a BMI of 27kg/m2 or above. In other words, heart protection is no longer just a secondary benefit of weight loss; for eligible patients, it is a formally recognised indication in its own right.
A real-world study of more than 21,000 patients[2], presented at the European Society of Cardiology Congress in Madrid and reported by Reuters, compared people who were overweight or obese with existing cardiovascular disease (but no diabetes) taking either Wegovy or Mounjaro. The headline findings were striking: major cardiovascular events occurred in just 15 people taking Wegovy, compared to 39 people taking Mounjaro - a 57% lower relative risk for Wegovy, and around 29% lower overall cardiovascular risk compared to tirzepatide.
It's important to be clear about what this study can and can't tell us. This was a real-world observational comparison, not a randomised controlled trial, and the average follow-up was relatively short at around 4 months - so more research is needed before drawing firm long-term conclusions. Mounjaro's effects on heart health specifically are also still under active study, which is part of why the comparison currently favours Wegovy on this measure. Both medications remain excellent, evidence-based choices for weight loss and metabolic health; if heart disease alongside obesity is a particular concern for you, this is worth discussing directly with your prescriber.
These real-world findings sit alongside the long-term SELECT trial data discussed above, where weight loss of around 10% was sustained for up to 4 years - even without further lifestyle changes - and Wegovy reduced heart failure hospitalisations. Together, this is some of the strongest evidence for any GLP-1 medication's cardiovascular benefit currently available.
Wegovy has been shown to help people who have certain types of heart failure with preserved ejection fraction (HFpEF). Research suggests that a significant proportion of HFpEF patients are obese, so Wegovy can contribute to weight loss, which can indirectly lead to a better quality of life for those who suffer from HFpEF.
In another study by Novo Nordisk[3], 529 patients were randomly treated with a weekly semaglutide injection once or a placebo for a year, and here are the findings:
A large study called the FLOW trial[4] looked at how semaglutide (Wegovy being a branded variety) can affect people with type 2 diabetes and chronic kidney disease.
Whilst research is still ongoing, here is what we know so far:
Fatty liver disease - now more accurately called MASLD, with its more severe inflammatory form known as MASH - is closely linked to obesity and affects around one in four adults in the UK. Because weight loss is one of the most effective ways to improve liver health, and Wegovy supports meaningful, sustained weight loss, it's a reasonable question to ask whether it helps here too.
In the ESSENCE trial[5], a large international study including UK participants, nearly 63% of people taking semaglutide experienced MASH resolution without their liver scarring getting worse, compared with 34% in the placebo group. More than one-third also showed improvement in liver fibrosis by at least one stage, compared with 22% in the placebo group. Other studies[6] have also shown semaglutide can lower ALT (a liver enzyme) and markers of inflammation, both of which are linked to ongoing liver damage.
It's important to be clear that Wegovy is currently licensed in the UK for weight management, not specifically for MASH or liver disease - any liver benefit is considered a secondary effect of weight loss rather than a licensed indication. If liver health is a particular concern for you, your prescriber can discuss this in more detail during your consultation.
Those who suffer from PMOS - Polyendocrine Metabolic Ovarian Syndrome also known as( PCOS) (Polycystic Ovary Syndrome) may also suffer from weight gain, irregular periods, acne, and/or extra hair growth as a result of the condition: this is caused by an increased insulin resistance, which makes it more difficult for your body to use sugar optimally. Wegovy can help. Taking Wegovy can make your periods more regular, lower insulin resistance, reduce acne and prevent excessive hair growth. In most meta analysis studies[7], about 80% of people who lost 5% of their body weight using Wegovy also showed better insulin control.
As with the liver health findings above, Wegovy is not specifically licensed to treat PMOS - any improvement in PMOS symptoms is considered a secondary effect of weight loss and improved insulin sensitivity, rather than a primary, licensed use of the medication.
Obesity is one of the main drivers of obstructive sleep apnoea, a condition where the airway becomes partially blocked during sleep, leading to interrupted breathing, poor sleep quality and daytime fatigue. Excess weight around the neck and chest narrows the airway, making blockages more likely.
Because Wegovy supports significant, sustained weight loss, it can meaningfully ease the airway narrowing that drives sleep apnoea - even a modest 5-10% reduction in body weight has been shown to reduce the frequency of breathing interruptions during sleep. Tirzepatide (the active ingredient in Mounjaro) has gone a step further: its sister medication, Zepbound, received FDA approval specifically for obstructive sleep apnoea in adults with obesity. While Wegovy doesn't currently hold an equivalent licensed indication for sleep apnoea, the underlying mechanism - weight loss easing airway obstruction - applies in the same way.
If sleep apnoea is a concern for you, it's worth mentioning to your prescriber alongside your weight loss goals, as it may affect your overall treatment plan and whether further investigations, such as a sleep study, are appropriate.
There's a growing, but still early, body of research looking at whether GLP-1 medications like Wegovy might reduce cravings for alcohol, nicotine and other substances. This isn't a licensed use of Wegovy, and the evidence so far comes mainly from animal studies, observational data, and a small number of early human trials.
A study published in JAMA Psychiatry found that people with alcohol use disorder reported drinking less and experiencing fewer cravings for alcohol and cigarettes over a nine-week period while taking semaglutide. Separately, an analysis of medical records[8] for more than 600,000 US veterans with type 2 diabetes found that GLP-1 use was associated with a 14% lower overall risk of developing alcohol, nicotine and other substance use disorders. The proposed explanation is that GLP-1 receptors exist not just in the gut, but also in dopamine-related reward pathways in the brain - the same pathways involved in addictive behaviour.
It's important to be clear that no GLP-1 medication, including Wegovy, is currently approved to treat addiction or alcohol use disorder, and researchers are explicit that significantly more evidence is needed before this could become an established use. This remains an active and genuinely interesting area of research to watch, rather than a reason to start treatment for this purpose.
Semaglutide has been shown to help improve blood sugar control, reduce inflammation as a result of weight loss, and improve insulin resistance. Each of these factors is also linked, indirectly, to cognitive health and general wellbeing - poorly controlled blood sugar and chronic inflammation are both associated with a higher long-term risk of cognitive decline.
Some early-stage research has explored whether semaglutide could have a more direct effect on brain health, including studies in animal models of Alzheimer's-like disease. This research is genuinely interesting, but it's important to be clear about its current limits: it has so far been conducted in mice, not in human patients, and findings from animal studies frequently don't translate directly to human outcomes. Larger human trials would be needed before any conclusions could be drawn about semaglutide's effect on conditions like Alzheimer's disease in people. For now, this remains an active area of research to watch, rather than an established benefit of treatment.
Pharmacists are trusted and regulated healthcare professionals who help patients make sense of medical developments. Whether its:
Your IQ Doctor pharmacist is here to guide you every step of the way, answer any nagging questions, and support your journey from prescription to progress. If you'd like to understand more about how Wegovy compares to other treatment options, see our Mounjaro vs Wegovy guide, or visit our Weight Loss Hub for the full range of treatment guides.
IQ Doctor is a registered UK pharmacy that specialises in medical remedies for weight loss, erectile dysfunction, hair loss support and much more. Whether you require over-the-counter relief, or prescription-only medication, the experts at iQ Doctor can assist. Please get in touch if you need any further advice.
Also, be sure to keep in touch with IQ Doctor via our social media channels as well as keeping up to date with us by signing up to the mailing list.
“Patients read a lot of bold claims about these medications. Our role is to give them the honest picture, including where the evidence is still developing. Wegovy's weight loss benefits are well established, and for the right patient the wider effects on heart, liver and kidney health can matter too. The place to work out what applies to you is a proper consultation with our clinical team”
Omar El-Gohary, Superintendent Pharmacist and CEO of iQ Doctor
No. Most of the trials discussed above, including the SELECT heart health trial and the STEP-HFpEF heart failure trial, used the standard 2.4mg maintenance dose - not a higher strength. These benefits aren't necessarily tied to taking more medication, but rather to the effects of weight loss and improved metabolic health at a dose many patients are already on.
Not at present. In the UK, Wegovy is licensed for weight management and for reducing cardiovascular risk in people with existing heart disease - it is not separately licensed to treat liver disease, kidney disease or PCOS. Any improvement in these areas is considered a secondary effect of weight loss and improved metabolic health, not a standalone treatment indication. If one of these conditions is a particular concern for you, it's still worth raising with your prescriber, as it may be relevant to your overall suitability and treatment plan.
Yes - always disclose any existing health conditions during your consultation, even if you're hoping Wegovy might help with them. This allows your prescriber to confirm Wegovy is suitable for you, check for any relevant precautions, and set realistic expectations about what it can and can't do for your specific situation. You can discuss this in detail during your online consultation with IQ Doctor.
This page has been written by a registered UK pharmacist and reviewed by our clinical team to ensure it is accurate, clear and reflects current clinical guidance.
Last medically reviewed: 11 February, 2026
Last updated: 13 October, 2026